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High-intensity exercises are known to provoke delayed onset muscle soreness (DOMS). Delayed onset muscle
soreness typically occurs within the first 24 h, peaks between 24 and 72 h, and can last as long as 5–7 days
post-exercise. Delayed onset muscle soreness is a multifactorial process involving both mechanical and biochem-
ical components, associated with clinical features that may limit range of motion, and athletes seek for effective
recovery strategies to optimize future training sessions. TensLess® is a food supplement developed to help man-
age post-exercise recovery. The supplement has been investigated on 13 recreationally active athletes of both sex,
during a randomized, double-blind, and crossover clinical investigation, including a 3-week washout period. The
clinical investigation was based on the study of TensLess® effects for DOMS management and on the reduction
of associated muscle damages following an eccentric exercise protocol. Supplementation with TensLess® induced
significant decrease in DOMS perception (33%; p = 0.008) as of the first 24 h; this was significantly correlated
with a lowered release of muscle damage-associated biomarkers, namely myoglobin, creatinine, and creatine ki-
nase, for the whole length of the recovery period. Taken together, these positive results clearly indicate that post-
exercise supplementation with TensLess® may preserve myocytes and reduce soreness following eccentric
exercise-induced damages, and, accordingly, significantly shorten muscle recovery. Copyright © 2017 John Wiley
& Sons, Ltd.
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INTRODUCTION
The practice of high-intensity exercise involving eccen-
tric muscle contraction, such as resistance training,
downhill running, resisted cycling, or stepping, is known
to provoke delayed onset muscle soreness (DOMS)
(Cleak and Eston, 1992). DOMS typically occurs within
the first 24 h, peaks between 24 and 72 h, and can last as
long as 5–7 days post-exercise (Howatson and van
Someren, 2008). DOMS is classified as a type I muscle
strain injury, and its associated clinical features include
discomfort, pain, swelling, tenderness, loss of strength,
and limited range of motion (Cheung et al., 2003).
Symptoms associated with DOMS are known to reduce
power and overall performance during subsequent
bouts of exercise (Clarkson and Hubal, 2002) and may
predispose individuals to injury (Cheung et al., 2003).
Thus, both athletes and recreationally active individuals
seek for effective recovery strategies to alleviate dis-
comfort and pain and to help optimize future training
sessions.
While the etiology of DOMS is still debated, recent
literature suggests that it is a multifactorial process
involving both mechanical and biochemical components
(Lewis et al., 2012). Eccentric contraction induces initial
structural damages to the active muscle, namely produc-
ing a disruption of the sarcolemma in which it is in-
creased an efflux of cytosolic proteins (Sorichter et al.,
1999). Therefore, damaged muscle may induce a pro-
inflammatory response with the release of chemokines
(Tidball, 2011), allowing the recruitment of inflamma-
tory cells at the site of lesions and a concomitant in-
crease in prostaglandins, which are known to activate
nociceptors and provoke acute pain and tenderness
(Connolly et al., 2003). Neutrophils and
monocytes/macrophages are then attracted to, and accu-
mulate at, the injured muscle cells. Collectively known
as leukocytes, they give rise to cytokines and amplify
the inflammatory response by recruiting additional leu-
kocytes (Connolly et al., 2003). Collaterally, through an
increased oxidative stress, they generate reactive oxy-
gen species (ROS) which also contribute to amplify in-
flammation and oxidative stress in damaged muscle
(Connolly et al., 2003). Thus, several factors seem to
contribute to DOMS etiology, explaining through corre-
sponding manifestations of muscle damage, the level
and occurrence of DOMS.
In an attempt to reduce the symptoms associated with
DOMS, non-steroidal anti-inflammatory drugs
(NSAIDs) are commonly prescribed post-exercise
* Correspondence to: Julien Cases, Fytexia, Innovation and Scientific Af-
fairs, 34350 Vendres, France.
E-mail: jcases@fytexia.com
PHYTOTHERAPY RESEARCH
Phytother. Res. (2017)
Published online in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/ptr.5902
Copyright © 2017 John Wiley & Sons, Ltd.
Received 08 March 2017
Revised 24 July 2017
Accepted 02 August 2017
(Schoenfeld, 2012). Their effects on the alleviation of
DOMS have been extensively studied, but the results
are conflicting. Some authors reported a decrement in
the perception of muscle soreness with prophylactically
administered NSAIDs (Hasson et al., 1993; Sayers
et al., 2001), while others failed to demonstrate any ef-
fect on pain relief of DOMS (Donnelly et al., 1990;
Barlas et al., 2000). Moreover, NSAIDs do not address
oxidative stress and the loss of muscle force linked to
DOMS (Tokmakidis et al., 2003); some authors even
suggest that NSAIDs could have detrimental effects on
muscle regeneration after injury (Trappe et al., 2002).
The chronic overuse of NSAIDs has also been related
to side effects such as hepatotoxicity, gastrointestinal
toxicity, and to renal insufficiency (Feucht and Patel,
2010). In this regard, both elite and novice athletes
experiencing exercise-induced muscle discomfort are
looking for natural and safe alternatives to address
symptoms associated with DOMS.
As a natural alternative to manage DOMS, polyphe-
nolic compounds have recently received growing atten-
tion from the scientific community with respect to their
well-studied antioxidant and anti-inflammatory benefits.
Among them, consumption of phenolic compounds
from pomegranate, mangosteen, and berry (Zafra-
Stone et al., 2007; Xie et al., 2015; Ghavipour et al.,
2017) have demonstrated beneficial effects on human
biomarkers of both oxidative stress and inflammation.
We hypothesized that such properties ascribed to poly-
phenolic compounds could be beneficial in reducing
muscle soreness and damages as the etiology of DOMS
is both inflammatory and oxidative (Connolly et al.,
2003). Few studies have examined the potential effects
of polyphenols in promoting recovery following a bout
of intense exercise (Kim and Lee, 2014), and most of
the studies have focused on the effect of a single pheno-
lic compound (Laupheimer et al., 2014) or a unique fruit
source such as juice (Trombold et al., 2011) or whole
fruit (McLeay et al., 2012).
TensLess® is an innovative food supplement pro-
duced from a blend of natural bioactive compounds ex-
tracted from the fruit of mangosteen, pomegranate, and
elderberry, which provide polyphenolic compounds,
mainly consisting of xanthones, ellagic acid, and
anthocyanins.
Thus, this prospective study aimed to investigate the
potential effect of TensLess® on the management of
DOMS and muscle damages, following an eccentric ex-
ercise protocol in healthy and recreationally active
volunteers.
MATERIALS AND METHODS
Ethics statement. The protocol of the study was ap-
proved by the Ethics Committee at the Catholic Univer-
sity of Murcia and conducted according to the guidelines
laid down in the Declaration of Helsinki (World Medi-
cal Association, 2013) and in compliance with Good
Clinical Practices defined in ICH Harmonized Tripartite
Guidelines (Vijayananthan and Nawawi, 2008). All par-
ticipants were informed about operating procedures of
the clinical trial, and they agreed to sign a written in-
formed consent form before entering the study.
Study population. Eighteen recreationally active volun-
teers of both sex (12 men and 6 women), in comparable
physical condition, with a minimum of 20 years old,
were recruited from in Catholic University of Murcia,
Spain.
Any individuals usually involved in high-intensity
training or with a history of cardiorespiratory problems
or chronic illness were not enrolled. In addition, individ-
uals with a history of orthopedic injury or surgery within
the last year or having any physical condition considered
a contraindication to the type of exercise performed in
the study were excluded. Also, those affected by any
medical condition or using any medication, nutritional
product, dietary supplement, or program which might
interfere with the conduct of the study or place the sub-
ject at risk were not included. Furthermore, individuals
could not participate if they had any food allergy to
mangosteen, pomegranate, elderberry, or corn.
Test supplement. TensLess®, supplied by FYTEXIA
(France), is principally obtained by alcohol and water
extraction of mangosteen (Garcinia mangostana L.)
and pomegranate (Punica granatum L.), by concentra-
tion of black elderberry (Sambucus nigra L.) juice.
TensLess® provides bioactive compounds, especially
polyphenols from xanthones, ellagitannins, and antho-
cyanins family. TensLess® complies with regulations on
food contaminants and on banned and prohibited sub-
stances. The placebo product was 100% maltodextrin,
which is polyphenol-free. Both TensLess® and placebo
were supplied in 500 mg capsules of identical appear-
ance and flavor.
Supplement was analyzed by means of high-
performance liquid chromatography (HPLC). An
Agilent HPLC 1260 apparatus (software Openlab CDS
chemstation edition) coupled with diode array detector
was used. Separation was carried out by mean of a
Zorbax Stablebond SB-C18 column (4.6 × 2 mm; 5-μm
particle size). To detect different phenolic classes, three
different analytical methods were adopted: one for
ellagitannins, one for xanthones, and one for
anthocyanins.
For ellagitannins, mobile phase A consisted of 6%
acetic acid, mobile phase B was 5% acetic acid and
30% acetonitrile and mobile phase C was 100%
acetonitrile. The program was as follows: (a) 5 min
100% A; (b) 5 to 10 min linear gradient from 0 to 40%
B; (c) 10 to 15 min linear gradient from 40 to 60% B;
(d) 15 to 20 min linear gradient from 60 to 75% B; (e)
20 to 25 min linear gradient from 75 to 90% B; (f) 25
to 30 min linear gradient from 90 to 100% B; (g) 30 to
35 min linear gradient from 0 to 100% C; (h) 35 to
40 min 100% C; (i) 40 to 45min linear gradient from 0
to 100% A. Monitoring was performed at 350 nm at a
flow rate of 1 mL/min and injection volume of 25 μL.
Ellagitannins were expressed as ellagic acid.
For xanthones, mobile phase A consisted of 85%
methanol. The program was 15 min 100% A. Monitor-
ing was performed at 250 nm at a flow rate of
1 mL/min and injection volume of 20 μL. Xanthones
were expressed as α-mangostin.
For anthocyanins, mobile phase A consisted of 10%
formic acid and 3% acetonitrile, and mobile phase B
was 10% formic acid and 50% acetonitrile. The program
was as follows: (a) 0 to 20 min linear gradient from 6 to
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20% B; (b) 20 to 35 min linear gradient from 20 to 40%
B; (c) 35 to 40 min linear gradient from 40 to 60% B; (d)
40 to 45 min linear gradient from 60 to 90% B; (e) 45 to
50 min 90% B; (f) 50 to 55 min linear gradient from 90
to 100% B; (g) 55 to 60 min 100% B; (h) 60 to 65 min
linear gradient from 0 to 94% A. Monitoring was per-
formed at 520 nm at a flow rate of 0.8 mL/min and injec-
tion volume of 10 μL. Anthocyanins were expressed as
kuromarin chloride.
Study design. The study consisted on a 5-week, random-
ized, double-blind, placebo-controlled, crossover pilot
clinical trial. Volunteers were randomly assigned using
an allocation sequence generated by a computerized
random number generator. Once enrolled, subjects re-
ceived either the test supplement or visually identical
placebo for the first supplementation period of 5 days.
After this initial period, volunteers were asked to return
the container containing remaining capsules, before
starting a washout period for 3 weeks. After the wash-
out step, they were enrolled for the second 5-day sup-
plementation period in which they received the
opposite supplement.
Volunteers were instructed to take three capsules
daily during the supplement periods. On day 1 (D1),
they performed the eccentric exercise protocol and took
three capsules in the ensuing minute following the train-
ing session. On the other days (D2 to D5), they ingested
three capsules daily at the end of the working day, which
corresponded to a 24-h lag time between two supple-
mentations. Participants reported to the UCAM Re-
search Center for High Performance Sport every day
throughout the course of the study, except during the
washout period.
Eccentric exercise protocol. At least 7 days prior to the
start of the protocol, volunteers participated in a famil-
iarization session in order to determine their individual
8-repetition maximum (RM) for the half-squat exercise.
This load was individually determined for each partici-
pant using standard multi-RM determination proce-
dures (Baechle and Earle, 2008). On this session,
subjects were instructed to perform the half-squat until
a 90° knee angle was achieved, following the eccentric
phase of the movement (this was practiced extensively).
At D1, volunteers performed eight sets of 8-RM half-
squats in order to induce muscle soreness in the knee ex-
tensors and flexors. The dynamic eccentric phase of the
half-squat lasted 3 s, as set by a digital metronome, and
was followed by a rapid knee and hip extension back to
the starting point. The eight sets were separated by
2 min of rest. If necessary, during the protocol, the loads
were adjusted to ensure that subjects completed the full
eight repetitions.
Assessment of perceived muscle soreness—primary out-
come. At D1, perceived muscle soreness was recorded
before the eccentric exercise (pre-exercise), at the end
of the eccentric training (post-exercise), and 1 h after
the end of the exercise (post + 1 h). Perceived DOMS
were also recorded on days following the exercise (D2
to D5).
A 10-cm visual analog rating scale (VAS) was used to
evaluate perceived muscle soreness (Lau et al., 2013).
The anchors at 0 and 10 cm corresponded to ‘no sore-
ness’ and ‘worst possible muscle soreness’, respectively.
The volunteers drew a line on the VAS corresponding
to their level of soreness.
Blood markers of muscle soreness—secondary out-
comes. Blood was collected from an antecubital vein
on D1 (pre-exercise, immediately post-exercise, and
1 h post-exercise) and from D2 to D5 only one sam-
ple daily, using a vacutainer system. One tube of
EDTA-treated blood was centrifuged (10 min,
3500g) to separate out the plasma. Another tube of
blood was clotted and centrifuged (10 min, 5000g)
to separate out the serum. Serum myoglobin concen-
tration and plasmatic both, creatinine concentration
and total creatine kinase (CK) activity were deter-
mined using assay kits obtained from Abcam,
Cambridge, UK.
Statistical analysis. Data sets were analyzed using
Statview software version 4.51.1 (Abacus Concepts,
Berkeley, CA). The data are expressed as mean ± stan-
dard deviation (SD). Normality was evaluated by the
Shapiro–Wilk test. During the length of the studied
exercise inducing DOMS, changes within and be-
tween both groups were analyzed using paired and
unpaired Student’s t-test. A minimum value of
p < 0.05 was selected as the threshold for statistical
significance.
RESULTS
Participant characteristics
Twenty volunteers were assessed for eligibility, and
two of them did not meet inclusion criteria and were
excluded from participation in the study. Among the
18 volunteers recruited in the study, 3 did not report
to the Research Center for personal reasons and 2
did not complete the training protocol due to conflict
with study schedule. Thirteen participants completed
the entire protocol and were included in the analysis
(Fig. 1).
Characterization of the phenolic profile of the
supplement
The total bioactive content corresponds to 14.61/100 g
dry matter. Ellagic acid and derivative contents are mea-
sured at 8.64/100 g; xanthone and derivative contents
are measured at 5.67/100 g; anthocyanin content mea-
sured at 0.3/100 g (Table 1).
Perceived muscle soreness
The mean perceived muscle soreness (DOMS), in re-
sponse to the eccentric squatting exercise, is illustrated
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in Fig. 2. Ratings of perceived DOMS were not differ-
ent pre-exercise and immediately post-exercise be-
tween the placebo and the supplemented populations.
At 1 h post-exercise, perceived DOMS in the placebo
group increased while it stabilized for supplemented
subjects; despite this was not significantly different,
nevertheless it highlights a noteworthy lower DOMS
perception (31%; p = 0.121) when compared with
placebo, which is confirmed from D2, the day after
(33%; p = 0.008). Indeed, perceived DOMS contin-
ued to gradually increase to reach a maximum at 48 h
post-exercise (D3) in both groups, but when compared
with placebo population, it was significantly lower
within the supplemented group (29%; p = 0.045),
and even their cumulated perceived soreness (area un-
der the curve) within these first 48 h was as well signif-
icantly lower (31%; p = 0.005) when compared with
placebo; on the total 5 days with DOMS, the cumulated
score was lower in the TensLess® group (28%;
p = 0.002); despite at the end of the recovery period
(D4 and D5), difference between both groups was not
significant.
Figure 1. Consolidated Standards of Reporting Trials flow chart of participants during the study intervention.
Table 1. Characterization of phenolic compounds present in the supplement.
Compounds Rt (min) Λ max (nm) Content (g/100 g)
Xanthone-like 1 3.7 243; 259; 318; 358 0.21
γ-Mangostin 4.7 243; 259; 318; 364 0.58
Xanthone-like 2 5.4 243; 259; 318; 374 0.19
α-Mangostin 7.7 243; 257; 317; 358 4.69
Cyanidin-3-O-glucoside 5.9 265; 516 0.05
Cyanidin-3-O-sambubioside 9.5 280; 518 0.25
Ellagic acid-like 1 13.2 254; 379 0.31
Ellagic acid 16.0 254; 367 8.33
Figure 2. Delayed onset muscle soreness scores in subjects re-
ceiving TensLess® or the placebo, at baseline (pre), immediately
following exercise (post), and during the recovery period
(post + 1H, D2, D3, D4, and D5). Values are mean ± SD
(n = 13). Asterisk superscript indicates an intergroup difference,
p < 0.05.
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Blood markers of muscle damage
Serum myoglobin levels were not significantly different
between the two groups at baseline and immediately af-
ter the eccentric exercise. Myoglobin values significantly
peaked, when compared with baseline, in both groups
1 h following the exercise (p = 0.0004 and p = 0.0127
for, respectively, placebo and supplemented groups);
however, the maximal value was significantly different
(p = 0.044) between the two groups, with a strong
279% increase compared with baseline in the placebo
group and with a weaker 114% increase within the sup-
plemented population. Serum myoglobin returned to
baseline values from D2 and remained at baseline levels
during the whole recovery period in both groups
(Fig. 3A).
At baseline (pre-exercise), both groups exhibited a
similar concentration of plasma creatinine. Just after
the eccentric exercise, the concentration significantly in-
creased (p = 0.002 and p = 0.003, respectively, for pla-
cebo and supplemented groups) and reached maximal
value with a non-significant difference of peak value be-
tween the two groups. During the recovery period, the
level of plasma creatinine gradually decreased in both
groups but with significant differences between the pla-
cebo and the supplemented populations as of 1 h after
exercise (p = 0.024) and also at D2 (p = 0.015) (Fig. 3B).
Between the two groups of volunteers, plasma CK
levels were not significantly different at baseline (pre-
exercise), neither immediately after the eccentric exer-
cise (post-exercise) nor during the first hour of the recov-
ery period. The eccentric exercise induced a peaked
concentration of plasma CK 24 h following muscle-
damaging exercise, and compared with baseline, plasma
CK levels increased significantly by 139% in the placebo
group (p = 0.006) and 103% within the supplemented
population (p = 0.005). Compared with this D2 peak,
the supplemented group displayed significant decrease
at D3 (p = 0.018), D4 (p = 0.004), and D5 (p = 0.032),
and concentrations returned to baseline values. Con-
versely, any decreases in CK levels in the placebo group
during the recovery period were not significant com-
pared with the peak at D2 and continued to be signifi-
cantly different to the baseline concentration (Fig. 3C).
DISCUSSION
This prospective study highlights the beneficial, both
acute and sub-chronic effects of the supplementation
with TensLess®, a polyphenol-rich extract-based food
supplement, on adverse symptoms associated with
DOMS, namely eccentric exercise-related markers of
muscle impairment.
The eccentric exercise, that is, weighted half-squats,
successfully induced DOMS, as evidenced by the re-
ported scores of perceived muscle soreness, which is in
Figure 3. Serum myoglobin concentration (A), plasmatic creatinine concentration (B), and plasmatic CK activity (C) in subjects receiving
TensLess® or the placebo, at baseline (pre), immediately following exercise (post), and during the recovery period (post + 1H, D2, D3,
D4, and D5). Values are mean ± SD (n= 13). Delta superscript indicates a difference as compared with baseline, p < 0.05. Asterisk super-
script indicates an intergroup difference, p < 0.05.
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line with previous studies (Shimomura et al., 2010;
Pearcey et al., 2015) where DOMS peaked at 48 h
(D3) following similar protocol. Also, the increased
levels of skeletal muscle enzymes and proteins in blood
circulation, such as myoglobin, creatinine, and CK, con-
firmed the induction of muscle damages following the
squat exercise, given that they are the most valuable
and direct markers of muscle injury (Brancaccio et al.,
2010). Accordingly, the protocol used to induce muscle
damages was appropriate for evaluating the potential ef-
fect of a dietary food supplement in managing DOMS.
The main symptom related to DOMS and for which
scientific researches are converging is pain, which is
known to limit both recovery and subsequent athletic
performances (Twist and Eston, 2005). The origin of
pain linked with DOMS is hypothesized to be induced
by the release of prostaglandin E2 (PGE-2), which sen-
sitizes types III and IV afferent nerve fibers through
nociceptors. Furthermore, inflammatory responses to
eccentric exercise would contribute to the sensation of
pain (Connolly et al., 2003). The post-exercise supple-
mentation significantly decreased cumulated perceived
soreness (DOMS) as evidenced with a 31% reduction
within the first 2 days post-exercise when compared with
the placebo group; similar result was obtained regarding
perceived pain (data not shown). Mechanisms supposed
to be linked to the beneficial effects of the supplement
on the alleviation of muscle soreness and associated
pain could be attributed to both direct antinociceptive
and indirect anti-inflammatory activities of phenolic
compounds. Indeed, beyond previously demonstrated
anti-inflammatory effects of α-mangostin (Chen et al.,
2008; Romain and Cases, 2015), a xanthone from poly-
phenol family naturally occurring in mangosteen, it has
recently been shown that this compound is able to in-
hibit both central and peripheral nociception in a rodent
model of induced pain through interaction with at least
three different physiological pathways linked to pain
perception (Sani et al., 2015). Apart from mangosteen
bioactive, phenolic compounds from pomegranate ex-
tract, and particularly ellagic acid, could also contribute
to decrease eccentric exercise-induced muscle soreness.
As with mangosteen, pomegranate extracts display
anti-inflammatory and, both central and peripheral,
antinociceptive properties in animal models (González-
Trujano et al., 2015). Trombold et al. (2010) reported
that an intake of 500 mg of ellagitannins twice a day dur-
ing a 5-day period preceding eccentric exercise was able
to reduce DOMS by 15% as of 2 h after muscle damage
induction. However, in the aforementioned study, no
significant differences between the placebo group and
the ellagitannin-supplemented population were found
within the 24 to 96 h post-exercise period (Trombold
et al., 2010). TensLess® also displays anthocyanins from
elderberry concentrate, which could potentiate the ben-
eficial effects of the supplement on eccentric exercise-
induced soreness and pain. Indeed, this was demon-
strated by previous researches in which an intake of tart
cherry juice, a fruit source of similar anthocyanins, was
found to be effective in reducing pain following long-
distance running (Kuehl et al., 2010). In the present
study, the supplement induced 29% reduction in per-
ceived soreness during the first 48 h corresponding to
the DOMS and pain peak period. This important sore-
ness and pain-alleviating benefit might be elicited by a
synergistic action of bioactive polyphenols that are at
the basis of TensLess® formulation and which are alto-
gether capable to provide both an acute and a sub-
chronic beneficial effect.
The half-squat protocol used in the present study, suc-
cessfully induced skeletal muscle injury, as exemplified
by the significant increase in typical blood markers of
damaged myocytes (Brancaccio et al., 2010), for which
both oxidative stress and inflammatory responses to ex-
ercise are suspected to be the principal culprits (Baird
et al., 2012). Even though no statistical difference was
found between the two groups with regards to CK peak
values, nevertheless the supplement significantly in-
duced a shorter return to baseline level at 48 h (from
D3), while in the placebo group, it remained not statisti-
cally different than peak level during the recovery
period.
Creatinine, although generally used as an indicator of
renal health, has also been shown to significantly in-
crease following high-intensity exercise (Levers et al.,
2015). In the present study, post-exercise levels of creat-
inine were in the normal range (0.7 to 1.2 mg/dL), indi-
cating no alteration of renal function but a normal
response to eccentric exercise with a significant time ef-
fect occurring in both groups just after the completion of
the squats protocol. While creatinine rapidly decreased
with a significant reduction from D2 and a return to
baseline value at D3 in the supplemented group, it sig-
nificantly remained at peak level for the placebo popu-
lation; this confirms a faster recovery with TensLess®.
Finally, this beneficial effect is confirmed with serum
myoglobin, another sensitive marker of muscle injury.
While the concentration peaked 1 h following the exer-
cise in both groups, a significant 25% lower increase in
the supplemented group was experienced when com-
pared with placebo.
Taken together, these positive results on direct bio-
markers of muscle damages clearly indicate that post-
exercise supplementation with TensLess® may preserve
myocytes from eccentric exercise-induced damages
which significantly enhance muscle recovery. The litera-
ture shows that eccentric exercise-induced oxidative
stress with increased reactive oxygen species release
would be among main contributory mechanisms of both
the initiation and progression of muscle damages
(Stagos et al., 2015). This may occur through an en-
hanced peroxidation of lipid membranes inducing then
after the disruption of muscle cells with a concomitant
efflux of cytosolic proteins (Jówko et al., 2015). In accor-
dance with the proposed biochemical mechanisms un-
derlying muscle damages, it may be hypothesized that
phenolic compounds from TensLess®, for which antiox-
idative properties have been extensively studied and
demonstrated in humans (Zafra-Stone et al., 2007;
Kondo et al., 2009; Matthaiou et al., 2014), effectively
may combine with their anti-inflammatory activities to
limit eccentric exercise-induced muscle damages
(Clarkson and Hubal, 2002; Sureda et al., 2014), thereby
explaining the decreased efflux of cytosolic proteins and
enzymes from the skeletal muscle into the bloodstream.
Thus, post-exercise supplementation with TensLess®
demonstrates a positive effect on both exercise-induced
DOMS and muscle damages, which explains the signifi-
cant faster recovery.
Nevertheless, further investigations need to be con-
ducted in order to validate the biochemical mechanisms
of action of phenolic compounds in relation to the
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amelioration of muscle injury by both their anti-
inflammatory and antioxidative properties. Addition-
ally, a pivotal study involving a larger sample of volun-
teers and incorporating high-profile athletes for which
athletic performance measurements during the recovery
period, namely strength and range of motion, would
have to be performed; this would let us allow to clearly
demonstrate the hypothesized mechanism implicated
during functional improvement following dietary sup-
plementation with TensLess®.
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